Research-grade peptide information.

Copper-binding tripeptide (Ala-His-Lys) studied alongside GHK-Cu in skin and hair research

AHK-Cu is a copper-binding tripeptide (Ala-His-Lys) sometimes paired with GHK-Cu in skin and hair research. The peer-reviewed literature directly on AHK / AHK-Cu is more limited than on GHK / GHK-Cu, and several papers focus on the related DAHK (Asp-Ala-His-Lys) human-serum-albumin N-terminal sequence rather than AHK itself.

Limited primary literature; documented as part of the broader copper-tripeptide research alongside GHK-Cu

Modified C-terminal fragment of human growth hormone (hGH 177–191)

AOD-9604 is a modified 16-residue C-terminal fragment of human growth hormone (residues 177–191) with an added N-terminal tyrosine. It was developed in the late 1990s–early 2000s as a candidate anti-obesity compound. Published primary research is dominated by rodent and rabbit models. AOD-9604 is not approved as a medicine.

Preclinical (rodent and rabbit) literature; Phase II clinical interest in early 2000s, limited published trial results

Non-hematopoietic erythropoietin-derived 11-residue peptide (cibinetide)

ARA-290 (cibinetide) is an 11-residue peptide derived from the helix B domain of erythropoietin. It engages the innate-repair receptor (a heterodimer of EPO-R and β common receptor) without stimulating erythropoiesis. Phase II clinical evidence exists in small-fibre neuropathy contexts; it is investigational at the time of writing.

Phase II clinical evidence in sarcoidosis small-fibre neuropathy and diabetic neuropathy; investigational